We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
Read MoreHide Full Article
Key Takeaways
Merck said tulisokibart met the primary and key secondary endpoints in late-stage UC Study 2.
MRK added tulisokibart via its $10.8 billion Prometheus Biosciences acquisition in 2023.
Merck is also testing tulisokibart in Crohn's disease and other inflammatory conditions.
Merck (MRK - Free Report) announced positive results from Study 2 of the late-stage ATLAS-UC study, which evaluated tulisokibart, its experimental human antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active ulcerative colitis (UC).
Study 2 evaluated tulisokibart as an induction therapy and met its primary endpoint of clinical remission at week 12. The study also met key secondary endpoints, including measures of endoscopic improvement and clinical response. However, Merck did not disclose detailed efficacy data supporting these outcomes.
The company plans to present the complete results from Study 2, along with data from the ongoing Study 1, at a future medical meeting. Study 1 is evaluating tulisokibart as both an induction and maintenance therapy, with patients being followed through week 52.
The positive results mark an important milestone for Merck as it seeks to diversify its portfolio beyond the blockbuster cancer drug Keytruda, which is expected to go off-patent in 2028. Keytruda currently accounts for roughly half of the company’s total revenues.
MRK’s Stock Performance
Year to date, the company’s shares have risen nearly 10% compared with the industry’s 3% growth.
Image Source: Zacks Investment Research
More on Merck’s Tulisokibart
The drug was added to Merck's pipeline in 2023 through its $10.8 billion acquisition of Prometheus Biosciences and is considered one of the company's important late-stage assets.
Apart from UC, tulisokibart is also being evaluated in a late-stage study for Crohn's disease. It is being developed in several mid-stage studies across multiple immune-mediated inflammatory diseases in rheumatology and dermatology. These include systemic sclerosis-associated interstitial lung disease, hidradenitis suppurativa, radiographic axial spondyloarthritis, rheumatoid arthritis and psoriatic arthritis.
Tulisokibart targets TL1A, a novel pathway involved in intestinal inflammation and fibrosis, that has emerged as a promising therapeutic target in inflammatory bowel disease. While Merck is among the leaders in this space, competition is intensifying. Other companies developing anti-TL1A therapies include Sanofi (SNY - Free Report) and Teva Pharmaceuticals (TEVA - Free Report) with duvakitug, as well as Spyre Therapeutics (SYRE - Free Report) .
View the Zacks #1 Rank List
Image: Bigstock
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
Key Takeaways
Merck (MRK - Free Report) announced positive results from Study 2 of the late-stage ATLAS-UC study, which evaluated tulisokibart, its experimental human antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active ulcerative colitis (UC).
Study 2 evaluated tulisokibart as an induction therapy and met its primary endpoint of clinical remission at week 12. The study also met key secondary endpoints, including measures of endoscopic improvement and clinical response. However, Merck did not disclose detailed efficacy data supporting these outcomes.
The company plans to present the complete results from Study 2, along with data from the ongoing Study 1, at a future medical meeting. Study 1 is evaluating tulisokibart as both an induction and maintenance therapy, with patients being followed through week 52.
The positive results mark an important milestone for Merck as it seeks to diversify its portfolio beyond the blockbuster cancer drug Keytruda, which is expected to go off-patent in 2028. Keytruda currently accounts for roughly half of the company’s total revenues.
MRK’s Stock Performance
Year to date, the company’s shares have risen nearly 10% compared with the industry’s 3% growth.
Image Source: Zacks Investment Research
More on Merck’s Tulisokibart
The drug was added to Merck's pipeline in 2023 through its $10.8 billion acquisition of Prometheus Biosciences and is considered one of the company's important late-stage assets.
Apart from UC, tulisokibart is also being evaluated in a late-stage study for Crohn's disease. It is being developed in several mid-stage studies across multiple immune-mediated inflammatory diseases in rheumatology and dermatology. These include systemic sclerosis-associated interstitial lung disease, hidradenitis suppurativa, radiographic axial spondyloarthritis, rheumatoid arthritis and psoriatic arthritis.
Tulisokibart targets TL1A, a novel pathway involved in intestinal inflammation and fibrosis, that has emerged as a promising therapeutic target in inflammatory bowel disease. While Merck is among the leaders in this space, competition is intensifying. Other companies developing anti-TL1A therapies include Sanofi (SNY - Free Report) and Teva Pharmaceuticals (TEVA - Free Report) with duvakitug, as well as Spyre Therapeutics (SYRE - Free Report) .
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
MRK’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.